Sobi, Ascendis Pharma, Zealand Pharma
Sobi: EU committee backs Tryngolza in severe hypertriglyceridaemia; Ascendis Pharma: EU committee backs once-weekly Yuviwel in achondroplasia; Zealand Pharma: ZP9830 well tolerated in multiple-dose Phase 1.
Sobi, Ascendis Pharma, Zealand Pharma Read Post »